Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43973   clinical trials with a EudraCT protocol, of which   7311   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2013-002077-21
    Sponsor's Protocol Code Number:AM-111-CL-13-01
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2015-09-11
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2013-002077-21
    A.3Full title of the trial
    Efficacy and Safety of AM-111 in the Treatment of Acute Inner
    Ear Hearing Loss
    Eficacia y seguridad de AM-111 en el tratamiento de la hipoacusia aguda en el oído interno
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Efficacy and Safety of AM-111 in the Treatment of Acute Inner
    Ear Hearing Loss
    Eficacia y seguridad de AM-111 en el tratamiento de la pérdida aguda de la audición del oído interno
    A.3.2Name or abbreviated title of the trial where available
    HEALOS
    A.4.1Sponsor's protocol code numberAM-111-CL-13-01
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAuris Medical AG
    B.1.3.4CountrySwitzerland
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAuris Medical AG
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAuris Medical Ltd.
    B.5.2Functional name of contact pointTomas Meyer
    B.5.3 Address:
    B.5.3.1Street AddressThe Black Church, St. Mary's Place
    B.5.3.2Town/ cityDublin 7
    B.5.3.3Post code1
    B.5.3.4CountryIreland
    B.5.6E-mailear@aurismedical.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEMEA/OD/013/05
    D.3 Description of the IMP
    D.3.1Product nameAM-111
    D.3.2Product code AM-111
    D.3.4Pharmaceutical form Gel for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPAuricular use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNAM-111
    D.3.9.2Current sponsor codeD-JNKI-1
    D.3.9.3Other descriptive nameXG-102
    D.3.9.4EV Substance CodeSUB114549
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number0.4
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEMEA/OD/013/05
    D.3 Description of the IMP
    D.3.1Product nameAM-111
    D.3.2Product code AM-111
    D.3.4Pharmaceutical form Gel for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPAuricular use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNAM-111
    D.3.9.2Current sponsor codeD-JNKI-1
    D.3.9.3Other descriptive nameXG-102
    D.3.9.4EV Substance CodeSUB114549
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number0.8
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboGel for injection
    D.8.4Route of administration of the placeboIntratympanic use (Noncurrent)
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Idiopathic sudden sensorineural hearing loss
    Tratamiento de la hipoacusia neurosensorial súbita idiopática
    E.1.1.1Medical condition in easily understood language
    Tinnitus
    Tinnitus (o acúfenos)
    E.1.1.2Therapeutic area Diseases [C] - Ear, nose and throat diseases [C09]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 18.0
    E.1.2Level PT
    E.1.2Classification code 10043882
    E.1.2Term Tinnitus
    E.1.2System Organ Class 10013993 - Ear and labyrinth disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Confirmation of the efficacy of AM-111 in the recovery of severe to profound idiopathic sudden sensorineural hearing loss (ISSNHL).
    Confirmación de la eficacia de AM-111 en la recuperación de la hipoacusia neurosensorial súbita idiopática de intensa a profunda.
    E.2.2Secondary objectives of the trial
    ? Further evaluation of the dose response relationship for AM-111 in the recovery of ISSNHL;
    ? Assessment of the efficacy of AM-111 in achieving complete remission of ISSNHL-related tinnitus;
    ? Assessment of safety and local tolerance of AM-111.
    - Evaluación exhaustiva de la relación entre la dosis de AM-111 y la respuesta en la recuperación de la HNSSI
    - Evaluación de la eficacia de AM-111 para alcanzar la remisión completa de los tinnitus relacionados con la HNSSI
    - Evaluación de la seguridad y tolerabilidad local de AM-111.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Unilateral ISSNHL with onset within 72 hours prior to study treatment;
    2. Mean hearing threshold of equal to or worse than major or equal 60 dB averaged across the 3 most affected contiguous air conduction audiometric pure tone frequencies ("pure tone average", PTA);*
    3. Mean hearing loss of equal to or worse than major or equal 40 dB averaged across the air conducted PTA frequencies compared with the unaffected contralateral ear or reference values from a pre-existing audiogram or ISO 7029;2000 norm values in case of asymmetric hearing prior to the ISSNHL incident;*
    4. Age major or equal 18 and minor or equal 65 years on the day of screening;
    5. Negative urine pregnancy test for women of childbearing potential. Women are not considered to be of childbearing potential if they meet one of the following criteria:
    - They have had a hysterectomy or tubal ligation at least one cycle prior to signing the Informed Consent Form (ICF) or
    - They are post-menopausal, with at least one year since their last menstrual period;
    6. Willing and able to attend the trial visits;
    7. Able to read and understand trial documents and follow Investigator instructions;
    8. Able to understand and follow trial personnel instructions during audiologic measurements;
    9. Willing and able to use adequate hearing protection and to refrain from engaging in activities or work involving loud noise exposure where sufficient hearing protection is not possible or ensured;
    10. Willing and able to protect the ear canal and middle ear from water exposure for as long as the tympanic membrane is not fully closed;
    11. Signed Institutional Review Board (IRB) / Independent Ethics Committee (IEC) approved ICF.
    1. HNSSI unilateral en las 72 horas anteriores al tratamiento del estudio
    2. Media del umbral auditivo mayor o igual a 60 dB o mayor (peor), promediada a partir de las 3 frecuencias contiguas más afectadas en la audiometría de tonos puros por conducción aérea («promedio de tonos puros», PTP)*
    3. Media de hipoacusia mayor o igual a 40 dB o mayor (peor), promediada mediante las frecuencias correspondientes al PTP por conducción aérea en comparación con los valores del oído contralateral no afectado o con los valores de referencia obtenidos en un audiograma anterior o los valores de la norma ISO 7029;2000 en caso de audición asimétrica antes del episodio de HNSSI*
    4. Edad mayor o igual 18 y menor o igual 65 años el día de selección
    5. Resultado negativo en una prueba de embarazo en orina (en mujeres con posibilidad de quedarse embarazadas). No se considera que las mujeres tengan posibilidad de quedar embarazadas si cumplen uno de los siguientes criterios:
    o Se han sometido a una histerectomía o ligadura de trompas como mínimo un ciclo antes de firmar el documento de consentimiento informado (CI) o
    o Son posmenopáusicas, habiendo transcurrido un año como mínimo desde la última menstruación
    6. Pacientes que quieran y puedan acudir a las visitas del estudio
    7. Pacientes que puedan leer y entender los documentos del estudio y seguir las instrucciones del investigador
    8. Pacientes que puedan entender y seguir las instrucciones del personal del estudio durante las determinaciones audiológicas
    9. Pacientes que quieran y puedan utilizar protección auditiva aceptable, y abstenerse de realizar actividades o trabajos que requieran una exposición a ruido elevado cuando no es posible o no puede garantizarse una protección auditiva suficiente
    10. Pacientes que quieran y puedan protegerse el conducto auditivo externo y el oído medio de la exposición al agua mientras la membrana timpánica no esté bien cerrada
    11. Pacientes que hayan firmado el CI que previamente haya aprobado el Comité Ético de Investigación Clínica (CEIC).
    E.4Principal exclusion criteria
    1. Bilateral ISSNHL;
    2. Acute hearing loss from noise trauma, barotrauma or head trauma;
    3. History of autoimmune hearing loss, radiation-induced hearing loss, endolymphatic hydrops or Menière's disease in the affected ear;
    4. History of chronic inflammatory or suppurative ear disease or cholesteatoma in the affected ear;
    5. History of acoustic neuroma or other retrocochlear damage in the affected ear;
    6. History of otosclerosis in the affected ear;
    7. Suspected perilymph fistula or membrane rupture in the affected ear;
    8. Congenital hearing loss;
    9. History of ISSNHL in the past 2 years;
    10. Otitis media or otitis externa that is ongoing or ended within 7 days prior to study treatment;
    11. Radiation therapy in the head and neck area within the past 5 years;
    12. Abnormality of the tympanic membrane in the affected ear that would preclude i.t. administration;
    13. Any pre-treatment within two weeks prior to enrolment, ongoing treatment or planned treatment of ISSNHL-related hearing loss or tinnitus including pharmacological medication or non-pharmacological treatment (other than prednisolone or prednisone reserve therapy following FUV2);
    14. Any therapy known as ototoxic (e.g. aminoglycosides, cisplatin, loop diuretics, quinine etc.) in the 3 months prior to trial inclusion;
    15. History within the past 2 years or presence of drug abuse or alcoholism;
    16. Subjects with diagnosed anxiety disorders, depression, schizophrenia or other significant psychiatric diseases requiring current drug treatment or subjects who required treatment in the previous 3 months prior to enrolment for any of these diseases;
    17. Any clinically relevant respiratory, cardiovascular, neurological disorder (except vertigo or tinnitus) or other abnormality that in the opinion of the Investigator or Sponsor may pose a safety risk to a subject in this study, which may confound efficacy or safety assessment, or may interfere with study participation;
    18. Known or suspected ongoing active infection of HIV, hepatitis C or B, or herpes zoster;
    19. Women who are breast-feeding, pregnant or who are planning to become pregnant during the study;
    20. Women of childbearing potential who are unwilling or unable to use an effective method of avoiding pregnancy from the screening visit until the end of the study (FUV4). Effective methods of avoiding pregnancy are contraceptive methods with a Pearl index of less than 1 used consistently and correctly (including implantable, injectable, oral and transdermal contraceptives, intrauterine devices, diaphragm with spermicide, male or female condoms with spermicide, or cervical cap, or a sterile sexual partner, or being abstinent);
    21. Concurrent participation in another clinical study or participation in another clinical study within 30 days prior to randomisation (TV).
    1. HNSSI bilateral
    2. Hipoacusia aguda provocada por traumatismo acústico, barotraumatismo o traumatismo craneoencefálico
    3. Antecedentes de hipoacusia autoinmunitaria, hipoacusia inducida por radiación, hidropesía endolinfática o enfermedad de Ménière en el oído afectado
    4. Antecedentes de enfermedad crónica del oído de carácter inflamatorio o supurante o colesteatoma en el oído afectado
    5. Antecedentes de neurinoma del estatoacústico u otra lesión retrococlear en el oído afectado
    6. Antecedentes de otoesclerosis en el oído afectado
    7. Posible fístula perilinfática o rotura de la membrana en el oído afectado
    8. Hipoacusia congénita
    9. Antecedentes de HNSSI en los 2 últimos años
    10. Otitis media u otitis externa persistente o resuelta en los 7 días previos al tratamiento del estudio
    11. Radioterapia en la zona de la cabeza y del cuello en los últimos 5 años
    12. Anomalías en la membrana timpánica del oído afectado que impidieran la administración i.t.
    13. Cualquier tratamiento previo en las dos semanas anteriores a la inclusión, o cualquier tratamiento en curso o tratamiento previsto para la hipoacusia o los tinnitus relacionados con la HNSSI, incluidos tratamientos farmacológicos y no farmacológicos (salvo tratamiento de reserva con prednisolona o prednisona tras la VSEG2)
    14. Cualquier tratamiento considerado ototóxico (como aminoglucósidos, cisplatino, diuréticos del asa o quinina) en los tres meses previos a la inclusión en el ensayo
    15. Antecedentes en los dos últimos años o presencia de drogodependencia o alcoholismo
    16. Pacientes con trastornos de ansiedad, depresión, esquizofrenia u otras enfermedades psiquiátricas significativas diagnosticadas que precisen tratamiento farmacológico en la actualidad o que lo hayan necesitado en los 3 meses anteriores a la inclusión
    17. Cualquier trastorno respiratorio, cardiovascular o neurológico (salvo vértigo o tinnitus) de interés clínico u otra anomalía que, en opinión del investigador o del promotor, pueda suponer un riesgo para la seguridad de un paciente en este estudio, pueda ocasionar una interpretación errónea de la evaluación de la eficacia o la seguridad o pueda interferir en la participación en el estudio
    18. Confirmación o presencia de infección activa persistente por el VIH, hepatitis B o C o herpes zóster
    19. Mujeres en periodo de lactancia, embarazadas o que tengan la intención de quedarse embarazadas durante el estudio
    20. Mujeres fértiles que no puedan o no quieran usar un método eficaz para evitar el embarazo desde la visita de selección hasta el final del estudio (VSEG4). Los métodos eficaces para evitar el embarazo son los métodos anticonceptivos con un índice de Pearl menor de 1, usados de forma constante y correcta (incluidos anticonceptivos implantables, inyectables, orales y transdérmicos; dispositivos intrauterinos; diafragma con espermicida; preservativos masculinos o femeninos con espermicida o capuchón cervical; o una pareja sexual estéril; o mantener la abstinencia sexual);
    21. Participación simultánea en otro estudio clínico o participación en otro estudio clínico en los 30 días previos a la aleatorización (VT).
    E.5 End points
    E.5.1Primary end point(s)
    Primary efficacy endpoint:
    Absolute improvement in PTA from baseline to FUV3.

    Primary safety endpoint:
    Occurrence of clinically relevant hearing deterioration (defined as increase in air conduction hearing threshold major or equal 10 dB at the average of any two contiguous test frequencies) from baseline to FUV3 in the treated ear. The analysis will be conducted also with bone conduction hearing threshold values.
    Criterio principal de valoración de la eficacia:
    Mejoría absoluta en el PTP desde el periodo basal hasta la VSEG3.

    Criterio principal de valoración de la seguridad:
    Aparición de deterioro clínicamente relevante de la audición (definido como un incremento en el umbral auditivo por conducción aérea mayor o igual 10 dB en el promedio de dos frecuencias de pruebas contiguas) desde el periodo basal hasta la VSEG3 en el oído tratado. También se realizará el análisis con los valores del umbral auditivo por conducción ósea.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Day 28
    Día 28
    E.5.2Secondary end point(s)
    Secondary efficacy endpoints:
    - Absolute improvement in PTA from baseline to FUV1, FUV2 and FUV4 ;
    - Proportion of subjects receiving corticosteroid reserve therapy;
    - Frequency of complete hearing recovery at FUV3 and FUV4;
    - Frequency of complete tinnitus remission at FUV4 in subjects with ISSNHL-related tinnitus at baseline.

    Secondary safety endpoints
    - Occurrence of clinically relevant hearing deterioration from baseline to all FUVs (other than FUV3) (air conduction) in the treated ear;
    - Difference in occurrence of clinically relevant hearing deterioration from baseline to all FUVs between treated and untreated contralateral ear;
    - Occurrence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs), differentiated by causal relationship to:
    - The IMP;
    - The intratympanic IMP administration;
    - Other trial procedures; or
    - Other reasons not related to the trial.
    Criterios secundarios de valoración de la eficacia:
    - Mejoría absoluta en el PTP desde el periodo basal hasta las VSEG1, VSEG2 y VSEG4
    - Porcentaje de pacientes que reciban tratamiento de reserva con corticosteroides
    - Frecuencia de recuperación completa de la audición en las VSEG3 y VSEG4 Frecuencia de remisión completa de los tinnitus en la VSEG4 en pacientes con tinnitus relacionados con la HNSSI en el periodo basal.

    Criterios secundarios de valoración de la seguridad:
    - Aparición de deterioro clínicamente relevante de la audición desde el periodo basal hasta todas las VSEG (salvo la VSEG3) (conducción aérea) en el oído tratado
    - Diferencia en la aparición de deterioro clínicamente relevante de la audición desde el periodo basal hasta todas las VSEG entre el oído tratado y el oído contralateral no tratado
    - Aparición e intensidad de acontecimientos adversos (AA) y acontecimientos adversos graves (AAG), diferenciados por relación causal con:
    o El PEI
    o La administración intratimpánica del PEI
    o Otros procedimientos del ensayo u
    o Otras razones no relacionadas con el ensayo.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Day 14, Day 28, Day 91
    Día 14, Día 28, Día 91
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned4
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA36
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Bulgaria
    Czech Republic
    Germany
    Hungary
    Poland
    Russian Federation
    Serbia
    Spain
    Taiwan
    Thailand
    Turkey
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLP
    LVLP
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 245
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 10
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state16
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 85
    F.4.2.2In the whole clinical trial 255
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    If needed, treatment or care after the subject has ended his/her participation in the trial will be the expected standard treatment of that condition.
    Si es necesario, el tratamiento después de que el paciente haya finalizado su participación en el ensayo será la práctica clínica habitual.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2015-09-17
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2015-09-04
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA